Journal article

Aberrant expression of LMO4 induces centrosome amplification and mitotic spindle abnormalities in breast cancer cells

Marjorie E Montanez-Wiscovich, Melissa D Shelton, Darcie D Seachrist, Kristen L Lozada, Emhonta Johnson, John D Miedler, Fadi W Abdul-Karim, Jane E Visvader, Ruth A Keri

The Journal of Pathology | WILEY | Published : 2010

Abstract

The LIM-only protein, LMO4, is a transcriptional modulator overexpressed in breast cancer. It is oncogenic in murine mammary epithelium and is required for G2/M progression of ErbB2-dependent cells as well as growth and invasion of other breast cancer cell types. However, the mechanisms underlying the oncogenic activity of LMO4 remain unclear. Herein, we show that LMO4 is expressed in all breast cancer subtypes examined and its expression level correlates with the degree of proliferation of such tumours. In addition, we have determined that LMO4 silencing induces G2/M arrest in cells from various breast cancer subtypes, suggesting that LMO4 action in the cell cycle is not restricted to a sin..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Institutes of Health


Awarded by Continuing Umbrella Research Experience (CURE)


Awarded by Department of Defense


Awarded by NATIONAL CANCER INSTITUTE


Awarded by NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES


Funding Acknowledgements

We thank William Bechtold for technical support and Gina Bernardo for help with manuscript preparation. We acknowledge the gene expression profile efforts of the International Genomic Consortium (IGC) and the Expression Project for Oncology (expO) and are also grateful for assistance from the Case Comprehensive Cancer Center core facilities (P30 CA43703). This study was supported by the following grants: National Institutes of Health RO1-CA090398 (RAK); Continuing Umbrella Research Experience (CURE) supplemental grant to RO1-CA090398 (RAK); National Institutes of Health T32-CA059366 (EJ); National Institutes of Health T32-GM007250 (MEMW); National Institutes of Health F31-CA123642 (MEMW); and Department of Defense W81XWH-09-1-0558 (MDS).